No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 259 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Early-onset cancer: why are more young adults being diagnosed? January 24, 2023 After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought February 8, 2019 Patient Guide in Prostate Cancer Now Available in Vietnamese December 10, 2025 De qué manera el seguimiento de los síntomas mejora la atención... May 6, 2021 Load more HOT NEWS Combination immunotherapy for advanced bowel cancer approved for NHS in England Mom Is Warning Other Parents After Her Son Was Bit By... Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar How Adolescent and Young Adult Cancer Survivors Can Cope With the...
